Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Cell Signal. 2016 Oct 1;29:52–61. doi: 10.1016/j.cellsig.2016.09.010

Figure 6.

Figure 6

Impact of timing of anti-angiogenic drug delivery relative to paclitaxel treatment on HCT-116 tumors growth. SCIDasmase+/+ mice harboring tumors were handled as in Figure 5A. DC101 (1.6 mg per mouse i.v.) was provided either before (A) or after (B) paclitaxel treatment. Mice harboring tumors were treated with paclitaxel (15/15/15 mg/kg i.p) three times biweekly. Data (mean±SD) were collated from 5 mice/group.